The prognostic significance of microRNA-221 in hepatocellular carcinoma: An updated meta-analysis.

IF 2.3 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

International Journal of Biological Markers Pub Date : 2021-06-01 DOI:10.1177/17246008211032689

Wenfeng Liu, Keshu Hu, Feng Zhang, Shenxin Lu, Rongxin Chen, Zhenggang Ren, Xin Yin

{"title":"The prognostic significance of microRNA-221 in hepatocellular carcinoma: An updated meta-analysis.","authors":"Wenfeng Liu, Keshu Hu, Feng Zhang, Shenxin Lu, Rongxin Chen, Zhenggang Ren, Xin Yin","doi":"10.1177/17246008211032689","DOIUrl":null,"url":null,"abstract":"Background: Recently, microRNA-221 has been found to be abnormally expressed in hepatocellular carcinoma; however, its clinical value has not been summarised. This meta-analysis aimed to assess the prognostic significance of miR-221 in hepatocellular carcinoma.Material and methods: PubMed, Science Direct, Web of Science, Scopus, Ovid MEDLINE, EMbase, Google Scholar, the Cochrane Library, CNKI, CBM, VIP and Wanfang databases were searched for eligible articles. The endpoints included overall survival, progression-free survival, recurrence-free survival, metastasis-free survival, disease-free survival. Hazard ratios with 95% confidence intervals were used to explore the relationship between miR-221 expression and clinical survival results of liver cancer patients. Subgroup analysis and sensitivity analysis were performed. Begg's test and Egger's test were conducted to evaluate publication bias.Results: A total of nine studies including 607 patients were recruited for this meta-analysis. The pooled hazard ratios displayed that high miR-221 expression was remarkably associated with poorer overall survival (hazard ratio = 1.91, 95% confidence interval: 1.53-2.38, p ＜ 0.01) and unfavourable progression-free survival/recurrence-free survival/metastasis-free survival/disease-free survival (hazard ratio = 2.02, 95% confidence interval: 1.58-2.57, p ＜ 0.01). The results of Begg's test and Egger's test did not exhibit obvious publication bias.Conclusions: High expression of miR-221 can predict poor outcome of hepatocellular carcinoma. miR-221 can be used as a promising prognostic biomarker of hepatocellular carcinoma.","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 2","pages":"17246008211032689"},"PeriodicalIF":2.3000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17246008211032689","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Background: Recently, microRNA-221 has been found to be abnormally expressed in hepatocellular carcinoma; however, its clinical value has not been summarised. This meta-analysis aimed to assess the prognostic significance of miR-221 in hepatocellular carcinoma.

Material and methods: PubMed, Science Direct, Web of Science, Scopus, Ovid MEDLINE, EMbase, Google Scholar, the Cochrane Library, CNKI, CBM, VIP and Wanfang databases were searched for eligible articles. The endpoints included overall survival, progression-free survival, recurrence-free survival, metastasis-free survival, disease-free survival. Hazard ratios with 95% confidence intervals were used to explore the relationship between miR-221 expression and clinical survival results of liver cancer patients. Subgroup analysis and sensitivity analysis were performed. Begg's test and Egger's test were conducted to evaluate publication bias.

Results: A total of nine studies including 607 patients were recruited for this meta-analysis. The pooled hazard ratios displayed that high miR-221 expression was remarkably associated with poorer overall survival (hazard ratio = 1.91, 95% confidence interval: 1.53-2.38, p ＜ 0.01) and unfavourable progression-free survival/recurrence-free survival/metastasis-free survival/disease-free survival (hazard ratio = 2.02, 95% confidence interval: 1.58-2.57, p ＜ 0.01). The results of Begg's test and Egger's test did not exhibit obvious publication bias.

Conclusions: High expression of miR-221 can predict poor outcome of hepatocellular carcinoma. miR-221 can be used as a promising prognostic biomarker of hepatocellular carcinoma.

查看原文本刊更多论文

microRNA-221在肝细胞癌中的预后意义:一项最新的荟萃分析

背景:近年来，人们发现microRNA-221在肝细胞癌中异常表达;然而，其临床价值尚未总结。这项荟萃分析旨在评估miR-221在肝细胞癌中的预后意义。材料与方法:检索PubMed、Science Direct、Web of Science、Scopus、Ovid MEDLINE、EMbase、Google Scholar、Cochrane Library、CNKI、CBM、VIP、万方等数据库。终点包括总生存期、无进展生存期、无复发生存期、无转移生存期、无疾病生存期。采用95%可信区间的风险比探讨miR-221表达与肝癌患者临床生存结果的关系。进行亚组分析和敏感性分析。采用Begg检验和Egger检验评价发表偏倚。结果:本荟萃分析共纳入9项研究，包括607名患者。合并风险比显示，高miR-221表达与较差的总生存期(风险比= 1.91,95%可信区间:1.53-2.38,p < 0.01)和不利的无进展生存期/无复发生存期/无转移生存期/无疾病生存期(风险比= 2.02,95%可信区间:1.58-2.57,p < 0.01)显著相关。Begg检验和Egger检验的结果没有表现出明显的发表偏倚。结论:miR-221高表达可预测肝细胞癌预后不良。miR-221可作为肝细胞癌的预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Biological Markers 医学-生物工程与应用微生物

CiteScore

4.10

自引率

0.00%

发文量

期刊介绍： IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.